Background: Arachidonate-5-lipoxygenase (5-LO) activity and increased
cysteinyl LTs (LTC4, LTD4, and LTE4) have been associated with asthma, allergy, inflammatory bowel disease, and autoimmune conditions, 1 LTB4 is considered the most proinflammatory 5-LO metabolite. 3 Interestingly, in contrast with the considerable number of COX inhibitors, currently there is only one 5-LO inhibitor (zileuton) that is US Food and Drug Administration-approved and used for the treatment of asthma. 4, 5 However, there is great interest in the therapeutic potential of inhibiting 5-LO, as a search on the US National Institutes of Health/National Library of Medicine online database in July/2017 for clinical trials returned 82 studies assessing 5-LO inhibitors (both isolated and in combination with other compounds) in the management of acute coronary syndrome, atherosclerosis, allergic rhinitis, various types of cancer (lung, prostate, head and neck, leukemia, lymphoma, and brain), lung inflammation, chronic obstructive pulmonary disease, pulmonary fibrosis, osteoarthritis, and sickle cell disease.
Periodontal disease is a chronic inflammatory condition, initiated and maintained by a complex microbial biofilm. Advanced forms are characterized by extensive destruction of non-mineralized connective tissues and extensive resorption of bone surrounding the teeth. 6 It is considered the most prevalent lytic disease of bone in humans. 7 Various studies in preclinical models report that inhibiting COX activity and prostaglandin production reduces tissue destruction. [8] [9] [10] [11] Clinical studies on the use of COX-2 inhibitors as an adjunct to periodontal therapy provide limited and somewhat controversial information regarding the added benefits in reducing tissue destruction, particularly considering possible side effects and cardiovascular risks associated with prolonged use of selective COX-2 inhibitors, [12] [13] [14] which limits their clinical application in periodontics for the short-term control of posttreatment inflammation and pain. 15, 16 Comparatively few studies have assessed the role of LTs in periodontal disease. [17] [18] [19] LTB4 is considered the most potent immunomodulatory leukotriene with potent proinflammatory effects, including the induction of leukocyte chemotaxis, production of reactive oxygen species, and proinflammatory cytokines such as interleukin (IL)-1, IL-6, and interferon-. 20 LTB4 also induces production of anti-inflammatory cytokines such as IL-4 and IL-10. 20 These effects have been associated with increased activation of nuclear factor-B (NF-B) and p38 mitogen-activated protein kinase signaling pathways in inflammatory cells subsequent to its interaction with both leukotriene B4 receptors (BLTR): BLTR1 (high-affinity, primarily expressed in immune cells) and BLTR2 (low affinity, expressed by immune cells and other cell types). 20 There is evidence that LTB4 is increased in the gingival crevicular fluid (an inflammatory exudate) 18 and in the saliva 17 of patients with periodontal disease. Moreover, there is evidence that LTB4 enhances osteoclast differentiation and activity by both receptor activator of NF-B ligand (RANKL)-independent 21 and RANKL-dependent mechanisms. 22 LTB4 may also negatively affect bone turnover by reducing osteoblast differentiation and activity. 23 Negative impact of LTs on bone turnover is also supported by the phenotype of increased cortical bone 24 and faster fracture healing 25 in 5-LO knockout mice. Besides its direct effects on bone turnover, LTB4 has a relevant role in the immune response due to its potent chemotactic effect on neutrophils, 2 monocytes/macrophages, 26 and on the increased migration and interaction of dendritic cells and T cells in the lymph nodes. 27 Activation of BLTR1 by LTB4 in dendritic cells increases production of IL-12. 28 Both cluster of differentiation (CD) 8 + and T helper (Th) 1/Th2 CD4 + T cells present increased expression of BLTR1, and its activation by LTB4 enhances recruitment of these cells to peripheral tissues. 29 The variety of biologic effects of LTB4 supports its role as an endogenous stimulator of innate immunity against exogenous pathogens and also as a bridge promoting the activation of adaptive immunity. 30 A decrease in neutrophil chemotactic response and consequently an impaired innate immune response was associated with an aggressive form of periodontitis. 31 Collectively, this information suggests that either the inactivation of LTB4 or its increased expression may affect inflammation and tissue destruction associated with periodontal diseases. To the best of the authors' knowledge, the only in vivo study assessing the role of LTs in periodontal disease used a hamster model of periodontitis in which production of LTs was suppressed using drugs that inhibit all LOs (5-, 12-, and 15-LO) non-specifically and reported a decrease of neutrophil infiltration and bone resorption. 19 Considering the relevant role of LTB4 in inflammation and immune response and the scarcity of information on its role in periodontal diseases, the present study assesses the effect of selective inhibition of 5-LO by an orally active compound in a murine model of lipopolysaccharide (LPS)-induced experimental periodontitis.
MATERIALS AND METHODS

Animals and experimental model
A total of 32 Balb/c mice (16 male and 16 female) aged 5 to 9 weeks were used. Seven female mice with a targeted disruption of 5-LO gene (5-LOKO) and four female wildtype (WT) mice of the appropriate background strain (129/Sv) were used as controls. Experimental periodontal disease was induced by local microinjections of 3 L of a 10-mg/mL LPS solution (from Escherichia coli, strain 055:B5) * into the gingival tissues adjacent to the palatal surface of the both maxillary first molars. Control animals were injected with the same volume of phosphate-buffered saline (PBS) (pH 7.4, no Ca/Mg, used to dilute the LPS) in the same anatomic regions. These injections were performed under inhalatory anesthesia (isofluorane) three times per week for 4 weeks by a trained operator (DEML) using microsyringes and customized needles of 30 Ga and 0.6-cm length. † The 32 Balb/c mice were divided into two groups of 16 animals (eight female and eight male), according to the bilateral injection of LPS or PBS. Half of the mice (eight animals, four females and four males) in each group (PBS or LPS) were treated with the 5-LO inhibitor ‡ by oral gavage daily (2 mg/kg, 200 L), and half were administered the same volume of the vehicle (0.025% non-ionic surfactant in 0.5% carboxymethylcellulose) in the same regimen and route. Oral gavage started the day before the LPS/PBS microinjections and continued until the day before euthanasia (28th day), which was done by inhalatory anesthesia followed by cervical dislocation.
5-LOKO mice and their WT controls were injected with LPS in the right hemimaxillae and with PBS vehicle in the left hemimaxillae (contralateral injections), serving as their own controls because of the limited number of animals available. Apart from the use of contralateral injections of PBS and LPS, the experimental procedures (anesthesia, injections, volumes, period, and euthanasia) were performed exactly as described for the Balb/c mice. All samples from the 5-LOKO mice were used only for the microcomputed tomography (micro-CT) scanning, as this experiment had the purpose of providing supporting information for a relevant role of 5-LO in this model.
All 64 hemimaxillae from 32 Balb/c mice were carefully resected immediately after euthanasia. Soft tissue from 32 * Sigma-Aldrich, St. Louis, MO. † Hamilton Robotics, Reno, NV. ‡ CJ-13610, Sigma-Aldrich. of these hemimaxillae was carefully resected (eight specimens in each of the four experimental conditions: PBS injections/vehicle, PBS injections/5-LO inhibitor, LPS injections/vehicle, and LPS injections/5-LO inhibitor). The standardized tissue sample (3 mm in the sagittal or anteroposterior plane × 2 mm in the frontal or latero-lateral plane) was immediately frozen in liquid nitrogen and kept at −80 • C until used. The remaining 32 hemimaxillae (eight from each experimental condition, four from male and four from female mice) were fixed in 4% paraformaldehyde for 24 hours at 4 • C and transferred to 70% ethanol for micro-CT scanning. After micro-CT scanning, tridimensional reconstruction, and verification of the scan quality, the 32 hemimaxillae that still had the untouched soft tissue were submitted to routine processing (including decalcification in 0.5% EDTA, pH 8.0) for paraffin embedding, sectioning, and subsequent histologic and immunohistochemical analyses.
Micro-CT analysis
Scanning was performed in 18-m slices, using preoptimized settings (50 kV, 300 mA, 0.5-mm aluminum attenuation filter) on a micro-CT equipment. § After tridimensional reconstruction, the resulting images were rotated in a standardized tridimensional orientation using defined anatomic references. A standardized threshold was set for the distinction of non-mineralized and mineralized tissues, and a defined region of interest (ROI) of 1,200 × 500 × 540 m (length × height × thickness) was set and positioned on the images according to anatomic landmarks. The fraction of mineralized tissue in the total volume of this ROI (bone volume/total volume [BV/TV]) was calculated using CT analyzer software. ¶
Histomorphometric and immunohistochemical analysis
Histomorphometric analysis was performed to assess the effect of 5-LO inhibitor on the inflammatory process in a standardized area of analysis. The area of analysis was defined at a distance of 300 m from the bottom of the junctional epithelium toward the center of the palate. This distance was defined on a digital image obtained at 50 × magnification. The field of image at 400 × magnification was positioned in this area using a defined landmark at this area, 300 m from the base of the junctional epithelium. Four microscopic fields at 400 × were used for the assessment of the inflammatory process. A total of nine semiserial sections (5 m thick) obtained in the frontal (buccal-palatal or latero-lateral) plane were assessed for each hemimaxilla, including three § Skyscan 1176, Bruker microCT, Kontich, Belgium. ¶ Skyscan v1.12.4.0, Bruker microCT.
histologic sections from each of three different regions spaced by 250 m in the sagittal/antero-posterior plane: 1) an "anterior region," corresponding to the midportion of the maxillary first molar; 2) a "central region," corresponding to the proximal area between the maxillary first and second molars; and 3) a "posterior region," corresponding to the midportion of the maxillary second molar. A total of 72 sections for each experimental condition (288 sections in total) were analyzed. An ROI was defined as five microscopic fields (600 × magnification), starting from the major palatal nerve/artery distally toward the teeth and including 40 m of the palatal bone. Polymorphonuclear neutrophils and mononuclear cells were differentially counted based on the nuclear morphology by a single trained and experienced examiner (CRJ), who was masked to the experimental condition.
Presence of osteoclasts was assessed by immunostaining for tartrate-resistant acid phosphatase (TRAP) associated with morphologic characteristics. Immunohistochemical staining required antigen retrieval in citrate buffer (pH 6.0) at 95 • C for 10 minutes. Staining was performed by incubation of the samples with polyclonal goat anti-TRAP antibody * at 1:400 for 18 hours at 4 • C in a humidified chamber. Controls included both isotype-specific irrelevant antibodies in the same dilution and the omission of primary antibodies. An avidin-biotin-horseradish peroxidase system was used for visualization † with hematoxylin counterstaining. Osteoclasts, defined as TRAP-positive large cells containing three or more nuclei in close proximity to the surface of the bone, were counted on the surface of alveolar bone beginning at the apex of the palatal root and extending up to a 500-m distance from the bottom of the junctional epithelium toward the mid-palate. For osteoclast counting, six sections (two sections from each of the three regions for the semiserial sectioning: "anterior," "central," and "posterior") were analyzed for each hemimaxilla. Four hemimaxillae (24 sections) were analyzed for each experimental condition, resulting in a total of 96 sections assessed. The same trained and experienced examiner counted the osteoclasts, also without knowledge of the experimental condition. Both osteoclast counting and the histomorphometric analysis were performed twice, with an interval of 6 weeks between assessments to verify consistency.
Enzyme-linked immunosorbent assay (ELISA) and LTB4 measurement
The eight soft tissue samples from each experimental condition that were kept at −80 • C were used for determination of LTB4 (five samples, two from female and three from male mice), IL-12, tumor necrosis factor (TNF), and IL-10 levels (three samples, two from female and one from male * cat# sc-8665, Santa Cruz Biotechnology, Dallas, TX. † LSAB2, Dako, Agilent Technologies, Santa Clara, CA. mice). Protein for the cytokine ELISAs ‡ was extracted from the tissue samples in detergent containing buffer § by mechanical disruption using a plastic pestle. Extraction of lipids for the LTB4 quantification was performed according to the manufacturer's recommendations of an enzyme immunoassay (EIA) kit. ¶ Total protein concentration was determined by the Lowry method # in an aliquot of each sample and used for the normalization of the cytokine ELISA results. The weight of each gingival tissue sample was used to normalize results of the LTB4 EIA kit. All assays were performed according to the manufacturer's instructions, and in all assays a minimum of 99% fit of the standard curve was obtained.
Statistical analyses
Data obtained from each experiment were analyzed using a statistical software package. ‖ The objective of analysis was to compare the results according to the different experimental conditions. As indicated in the figure legends, unpaired Student t tests with Welch correction were used for unequal variances and analysis of variance (ANOVA) with post hoc Tukey test was used for pairwise comparisons. Significance level was set at 95% (P < 0.05) in all analysis.
RESULTS
Oral administration of 5-LO inhibitor effectively reduces the production of LTB4 in inflamed gingival tissues
LPS injections caused a significant increase (>200%) in the level of LTB4. Daily administration of 2 mg/kg of 5-LO inhibitor by oral gavage was not associated with significant changes in behavior or weight of the animals (data not shown). This dosage was sufficient to significantly reduce (23.7% decrease) the production of LTB4 in the gingival tissues injected with LPS (Fig. 1). 
Inhibition of 5-LO attenuates inflammatory bone resorption and reduces osteoclast numbers
Inflammatory bone resorption was significantly attenuated in the animals treated with the 5-LO inhibitor (Fig. 2) . The relevance of 5-LO for inflammatory bone resorption is supported by the results observed in 5-LOKO mice (Fig. 3) . . This is an unexpected result, but the authors consider that the fact that the difference approaches statistical significance is indicative that either the sample size was too small to allow for the detection of significance or that other variables (such as the different strain of mice) may have also interfered with these results. Inhibition of bone resorption in 5-LO inhibitor-treated mice is accompanied by a significant decrease in the number of osteoclasts in close proximity to the alveolar bone surface (Fig. 4) .
Because the PBS injections did not induce bone resorption in either vehicle-or 5-LO inhibitor-treated mice (Fig. 2) , and considering the purpose of assessing the effect of pharmacologic-based inhibition of 5-LO on inflammation and bone resorption in this model, the remaining outcomes were analyzed only for PBS-injected/vehicle-treated, LPSinjected/vehicle-treated, and LPS-injected/5-LO inhibitortreated samples.
Severity of inflammation is reduced in the tissues of animals treated with 5-LO inhibitor
Histomorphometric analysis showed a significant decrease in the number of both polymorphonuclear neutrophils (PMNs) and mononuclear cells in gingival tissues (Fig. 5) , which is associated with a decrease in the levels of proinflammatory cytokines TNF and IL-12 (p70). A discrete, but non- (Fig. 6 ).
DISCUSSION
The purpose of this study is to assess the role and relevance of 5-LO in inflammation and bone resorption in a murine model of periodontal disease. This study focused on the use of an orally active biochemical inhibitor of 5-LO to provide a pharmacologic therapeutic perspective. Inhibition of the activity of 5-LO reduced inflammatory bone resorption and inflammation in the LPS-induced model of experimental periodontal disease. The decrease of inflammatory bone resorption was associated with fewer osteoclasts, reduced infiltration of PMNs and mononuclear cells, and a diminished production F I G U R E 3 A) Representative images of tridimensional reconstructions of micro-CT scanned hemimaxillae according to the genetic background (5-LOKO or WT control) and experimental condition (injections of PBS vehicle or LPS). Images are prepared in the same magnification, and all views are from the palatal side of the hemimaxillae. B) Quantitative analysis of the BV/TV in the ROI of the reconstructed tridimensional images, as described in Figure 2 . Note that the background strain 129/Sv is less susceptible to periodontal disease than the Balb/c strain shown in Figure 2 . Data derived from 14 hemimaxillae from 5-LOKO mice (seven animals, which received contralateral injections of LPS and PBS) and eight hemimaxillae from WT control mice (four animals, which received contralateral injections of LPS and PBS). Results were compared with the arbitrary 100% value (indicating no bone resorption) in PBS-injected WT control mice by one-sample t test. The percentage BV/TV between experimental conditions (PBS × LPS injections) was compared in each genotype (5-LOKO or WT) by unpaired t test with Welch correction for uneven variances. *P values for the relevant comparisons indicated in the figure. NS = not significant of proinflammatory cytokines such as TNF and IL-12 in the gingival tissues.
Increased 5-LO activity has been associated with periodontal tissue destruction in humans, seen indirectly by the observation of increased levels of LTB4 in the gingival tissues and in the gingival exudate of patients or sites with disease. 17, 32 Administration of a selective inhibitor of 5-LO by oral gavage reduced the production of LTB4 in inflamed gingival tissues by 23.7%, and this inhibition was sufficient to impair the inflammatory bone resorption associated with the LPS model of experimental periodontitis. These results were confirmed by using mice that were genetically deficient in functional 5-LO (5-LOKO mice) in the same LPS-induced experimental model of periodontal disease, which presented an attenuation of inflammatory bone resorption that was not statistically different from those observed with the use of the biochemical inhibitor. These results are also supported by studies inhibiting LTB4 or LTB4 receptors in rheumatoid arthritis models. 33 However, to the best of the authors' knowledge, this is the first study to use a pharmacologic approach to actively and selectively inhibit 5-LO in an experimental model of periodontal disease. It is also important to take the results of the experiment using 129/Sv background mice (5-LOKO and WT) as a supporting experiment to provide additional evidence of the biologic relevance of 5-LO to the inflammatory bone resorption in the LPS-induced model of periodontal disease. The results of the experiment using Balb/c mice and the pharmacologic 5-LO inhibitor are not compared with the results of the experiment using mice that are genetically deficient in 5-LO because of differences in strain, sex (only female 129/Sv mice were used), or because the absolute deficiency of functional 5-LO enzyme is not comparable with the partial inhibition achieved with the pharmacologic inhibitor.
Other noticeable effects observed with the administration of the 5-LO inhibitor were the decrease in the numbers of osteoclasts as well as numbers of PMNs and mononuclear cells infiltrating inflamed gingival tissues. This reduction in inflammatory cells may be due to reduced chemotactic stimulus caused by diminished LTB4 production. In turn, the decrease in numbers of inflammatory cells also reduced prevalence of mononuclear osteoclast precursor cells, significantly diminished the production of proinflammatory TNF and IL-12, and discretely increased production of IL-10 in gingival tissues. Observations from in vitro experiments using cells from 5-LO-deficient mice yielded similar results, 34 suggesting the results of this study are indeed associated with a decrease in the activity of 5-LO. LTB4 has been shown to induce bone resorption both in vitro and in vivo, 35 and there is evidence that reducing LTB4 activity would also impair osteoclastogenesis. 36 Recently, systemic inhibition of 5-LO by a pharmacologic agent has been shown to inhibit early osteoclastogenesis in a murine model of apical periodontitis associated with root canal contamination; however, in contrast with results of the present study, long-term inhibition of 5-LO actually increased bone resorption and osteoclast formation. 37 Importantly, in the early periods assessed in the periapical disease model, there was a significant decrease in expression of the prototypical proinflammatory cytokine IL-1 , 37 which supports the idea that inhibition of 5-LO has an attenuating effect on inflammation. It is important to consider that discrepancies between the study in the periapical infection model and the present study may be attributed to various factors, including mouse strains used (C57BL/6 versus Balb/c) and different experimental models (periapical lesion model with live endogenous bacteria versus sustained introduction of bacterial LPS into the gingival tissues). Distinct pharmacologic inhibitors were used: in the periapical model, the authors used MK886, 37 which binds to 5-LO activating protein (FLAP) but can also interfere with COX activity, 38 whereas the compound used in the present study is a non-redox-type inhibitor that acts by a competition with arachidonic acid (independent of FLAP-binding). Its efficacy does not depend on the nature of the cell stimulus or on the 5-LO-activating pathway. 39 These inhibitors may also differ in their pharmacokinetic properties, such as adsorption rate, maximum serum concentrations, and half-life. Differences in the methods used may also account for the discrepancies between studies, as the assessment of bone resorption in the periapical model 37 was performed by histomorphometric analysis (less precise than micro-CT), and the authors based all their gene regulation analysis on messenger RNA expression, which is not always exactly coupled with protein production.
The present study focuses on LTB4, not the cysteinylcontaining leukotrienes, because it is the most potent proinflammatory leukotriene; however, the authors cannot rule out the possibility that other 5-LO metabolites, such as 5-Hydroxyeicosatetraenoic acid (5-HETE), the initial cysteinylleukotriene LTC4, and its metabolites LTD4 and LTE4 may also play a role in inflammation and tissue destruction in this experimental model. Also, the production of anti-inflammatory and proresolving lipoxins (LXs) could be affected by inhibition of 5-LO activity in this study, as this enzyme participates in the two-step processes of transcellular biosynthesis of both LXA4 and LXB4. 1 It is important to note, however, that in the experimental model of periodontal disease used, there is sustained stimulation with the diseaseinducing agent (LPS), and consequently the role of LXs may not be critically relevant in this model.
Moreover, it is important to observe that the biochemical inhibitor was administered orally, and thus the local effects assessed in this study are exclusively due to the systemic effects of the inhibitor. It is tempting to speculate that, given the relevance of 5-LO in this experimental model, future studies may assess the use of novel formulations that restrict the effects to the inflamed area, without systemic effects.
Also, inhibition of 5-LO may shift the arachidonic acid metabolism to the COX/prostaglandin pathway, which would affect the inflammatory response. The literature is controversial, reporting both increases 40 and no difference 41 in prostaglandin production by macrophages from 5-LOdeficient mice. Interestingly, shunting of arachidonic acid to the 5-LO pathway has been shown in humans treated with selective COX-2 inhibitors, and the resulting increase in LTE4 was proposed as a possible link between the use of COX-2 inhibitors and cardiovascular complications. 42 Because LTB4 has been shown to be an endogenous ligand for Peroxisome proliferator-activated receptor (PPAR)-, it is important to consider that inhibition of 5-LO and the subsequent decrease of LTB4 may also impair anti-inflammatory/resolution processes mediated by this pathway. 43 Active destruction of periodontal tissues has been generally associated with a skew toward proinflammatory Th1 and/or Th17 phenotypes, 44 whereas inhibition of 5-LO has been reported to skew Th-type responses to a Th2 phenotype. 34 Shifting of Th-type phenotype responses may also be involved in the mechanism whereby inhibition of 5-LO attenuates periodontal tissue destruction in chronically inflamed gingival tissues. On the other hand, 5-LO was recently shown to be a negative regulator of Th1-type responses in mice infected in the peritoneum with Gram-negative bacteria. 45 These are speculative possibilities that were not directly assessed in this study and should be considered with caution but represent a possible point of intersection between 5-LO activity and adaptive immunity in host-microbial interactions occurring during periodontal disease.
It is important to consider the limitations and peculiarities of the experimental approach used in this study, particularly the use of the Balb/c strain of mice, which is more susceptible to experimental periodontal disease 46 and presents a different immunologic response 47 when compared with the more commonly used C57BL/6 strain. This is particularly relevant, as there is evidence indicating that the role of LTs in arachidonic acid-induced inflammation varies according to the mouse strain and also with the tissue compartment assessed in a given strain of mice. 48 The authors have not assessed the effect of the studied orally active inhibitor on the production of other 5-LO metabolites, including cysteinyl-leukotrienes and the antiinflammatory LXs; thus it is possible that some of the outcomes are influenced by modulation of LTD4, LTE4, LXA4, or LXB4. Inhibition of 5-LO has been shown to reduce production of inducible nitric oxide synthase (iNOS), the responsiveness to Toll-like receptor 4 (TLR4) activation, and also the activation of NF-B, 49, 50 which may also influence the outcomes of bone resorption and inflammation assessed in this study. To minimize this possibility, the authors have selected a dose of 2 mg/kg based on pilot experiments (data not shown), which was the lowest dose of inhibitor that had a biologic effect in vivo.
CONCLUSIONS
Overall, the results indicate that 5-LO may be, to the best of the authors' knowledge, a novel therapeutic target candidate in periodontitis; however, subsequent studies will assess how other 5-LO metabolites (cysteinyl-LTs and LXs) and COX metabolites (notably PGE2-prostaglandin E2) are affected by the inhibition of 5-LO. It is important to understand the possible effects of inhibiting 5-LO on the production of proresolution mediators and on the healing process, once the aggression has been reduced/eliminated. Inhibiting either LTA4 hydrolase or the high-affinity receptor BLTR1 will also be performed in future studies to assess the specific role of LTB4 in inflammation and bone resorption in this model. In conclusion, the data presented in this study support a relevant role for 5-LO in inflammation and bone resorption in the LPS model of experimental periodontal disease.
